To study the effects of treatment with a drospirenone pill (DRSP) (with ethinyl oestradiol, EE) in Indian women with polycystic ovary syndrome (PCOS).
Introduction
Polycystic ovary syndrome (PCOS) is one of the most common gynaecological endocrinological disorders. Ethnic background of women with PCOS may affect the clinical, hormonal and metabolic characteristics of this condition. Response to treatment of PCOS in Asia may be different from those in Western countries (1) . Indians are an ethnic group at particularly high risk for central obesity, type 2 diabetes mellitus and dyslipidaemia, all resulting from a state of insulin resistance (IR). Interaction of environmental factors (obesity) with the genetic factors finally results in the characteristic metabolic and menstrual disturbances and the final expression of the PCOS phenotype (2) . For a long time, combined oral contraceptives containing ethinyl oestradiol (EE) and a progestogen, have been used to treat these women. This combination can suppress the pituitaryovary axis, increase sex hormone binding globulin (SHBG) level and can cause lowering of "free" androgen level (3) . The new progestogen drospirenone (DRSP) derived from 17-alpha-spironolactone is found to have a pharmacological profile similar to that of natural progesterone with clinically relevant antimineralocorticoid activities and antiandrogenic activities and has been claimed to have the potential to reduce body weight and blood pressure (BP) (4) . Many studies have shown that oral contraceptives can cause deterioration of IR (5, 6) . This study was performed to evaluate the effects of EE/DRSP on various hyperandrogenic (clinical and biochemical) and metabolic parameters in Indian women with PCOS.
Materials and Methods
This was a prospective, open label, single arm study. The Ethics committee of S.C. Das Memorial medical and research center approved the study protocol and subject consent was obtained at study initiation. Fifty-one unmarried women (age ranges 15-32 years) presenting with the complaints of oligomenorrhoea (≤ six menses per year), with clinical evidence of hyperandrogenism (hirsutism and /or acne) were studied at the gynaecology clinic of the first author. PCOS was diagnosed as per the Androgen Excess Society 2006 criteria (7) . Detailed clinical and hormonal tests were done, as per the said criteria. Secondary causes of hyperandrogenism such as 21-hydroxylase deficiency, Cushing's syndrome, hypothyroidism, hyperprolactinaemia, and androgensecreting tumors were excluded by appropriate clinical and / or laboratory tests. All patients underwent ultrasonographic examination of the lower abdomen to note the status of their ovaries. In India, transvaginal ultrasonography cannot be performed in unmarried girls. All women had an ovarian volume of more than 10 cc. Exclusion criteria included adolescent girls with a gynecologic age (age since menarche) less than three years; those who had used oral pills in the preceding three months, those with known diabetes or hypertension or having treatment known to affect glucose metabolism such as corticosteroids. During clinical examination, the height, weight, abdominal circumference (AC), blood pressure (BP) were recorded. The procedures followed have been reported previously (8) . Body mass index (BMI) (as kg / m 2 ) was calculated in each case from height and weight measurements. BP was measured in each case by Korotkoff sound (stage V was used to determine the diastolic pressure). Hirsutism scoring was done as per the modified Ferriman-Galwey score (mFG score) (9) . Patients using cosmetic measures were requested not to depilate for at least one month before evaluation. To avoid interobserver error, the first author (SMB) himself graded the degree of hirsutism. The mFG score of ≥ 6 was considered as hirsutism. Presence of acne and acanthosis nigricans (AN) was noted in each case and reported as "Yes/No. The number of cases having acne and AN were expressed at each time point as % of patients with acne and AN present. The following biochemical tests were carried out on the second/third day of a progestogen-induced bleedingSerum total testosterone (TT); sex hormone binding globulin (SHBG); fasting insulin and plasma glucose levels (after 8-10 hours fasting). "Free Androgen Index" (FAI) was calculated as per the following formula After initial clinical and laboratory evaluation, each patient was advised to take a combination of EE (30 mcg) / DRSP (3 mg) (Yasmin R , Bayer Scherring Pharma, Berlin, Germany) 1 tablet daily from the first day of her menstruation for 21 days then a 7 day gap and again for 21 days and so on cyclically. Each patient was advised to continue the tablet for 6 cycles, then to repeat the tests as done at the beginning and clinically evaluated at the first follow-up visit at the first author's clinic. The final review was performed with another set of the same tests and clinical assessments after 12 months of treatment at the second followup visit.
Statistical analysis Sample size calculation:
The primary outcome to be measured was a drop in the mean serum testosterone level of 0.15 ng / ml. The study assumed a standard deviation of 0.25 at baseline and 0.22 at study end, based on previous samples. Assuming a correlation coefficient of zero, for 5% level of Significance and 80% power, for a one-sided test, the study required 42 patients. Analysis: A per-protocol analysis was done at study end using Graphpad Instat version 5.0. Repeated measures ANOVA with Tukey's post-test was used for parametric variables, Friedman ANOVA with Dunn's post-test for non-parametric variables. Dichotomous parameters were analyzed with Chi-square test.
Results
At study initiation, the participants were aged 22.2±5.4 years (mean±SD). Table 1 shows the mean±SD values of BMI in kg/ M 2 (minimum 21 to maximum 35), AC (cm), presence of acne and AN (in %), systolic blood pressure (SBP), diastolic blood pressure (DBP), fasting sugar (mg%), fasting insulin (mcu /ml) and G: I ratio of the subjects at the three points of study, namely at baseline (0 month), 6 month and 12 months. It shows that there are no significant changes in the values of BMI, AC, presence of AN, SBP, DBP between 0 months and 6 months and 6 months and 12 months. However, the percentage of patients having acne was reduced significantly from baseline to 12 months (p<0.05). Table 2 shows the results for FG score, serum testosterone, serum SHBG and the free androgen index (FAI). It is found that with EE/DRSP, there is significant improvement in the FG score (p<0.005). The testosterone level reduced significantly after 6 months of treatment and this reduction was maintained at 12 months (p<0.001). Serum SHBG showed a very signifi-cant rise (p<0.001) after 6 months of treatment with EE/DRSP and remained significantly high at 12 months. The FAI similarly showed a very significant fall at 6 months (p<0.001) and remained suppressed at 12 months.
Discussion
In this study the authors report their clinical experience on the use of EE/DRSP in Indian women with PCOS. Yu Ng et al (1) had stressed that it is important to take into consideration the ethnic background of patients in future studies related to PCOS. Table 2 shows that the trend in improvement in various hyperandrogenic manifestations are also maintained even after 6 months of treatment. Darney (10), Cerel-Suhl et al. (11) reported that EE/DRSP combination can help to obviate the common adverse effects found with the use of pills containing nortestosterone derivatives. DRSP possesses a strong antigonadotropic activity per se. Muhn et al. (12, 13) in animal studies has shown that DRSP can cause significant reduction of plasma LH levels. This LH lowering effect of DRSP may be one of the mechanisms by which the hyperandrogenic manifestations are reduced. Our study has shown a significant reduction of testosterone level by 6 months of treatment and also after 12 months of treatment. Krattenmacher (14) has shown that EE/DRSP combination can inhibit the steroidogenic enzymatic activities at the ovarian level Our study has also shown significant improvement in cosmetically unacceptable signs of hyperandrogenism namely, acne, hirsutism. Hirsutism is in part ethnically determined, being more common in women with dark skin (15). Zarger et al. (16) in a study from Kashmir, India found that 10.1% had mild hirsutism (F: G score 6-9) and 0.4% had moderate hirsutism (F: G score [10] [11] [12] [13] [14] . DRSP has been reported to have antiandrogenic effects even in the peripheral level also, by repression of androgen receptor-mediated transcription. DRSP can competitively bind to androgen receptors, because of its intrinsic molecular structure (17) . Low SHBG level in PCOS may be an intrinsic feature of the syndrome and this cannot always be explained by obesity alone because low SHBG has been reported in lean PCOS women also. Our study shows that there is a significant rise in SHBG level by 6 months of treatment and this trend is maintained even after 12 months of treatment. Consequently, FAI level shows the same trend. This stimulatory effect is due to the EE content of the medication. This shows that DRSP does not antagonize this stimulatory effect of EE on SHBG level in contrast to the progestogen derived from 19-nortestosterone. This action can also explain the significant amelioration obtained in the various manifestations of hyperandrogenism (14) . Our study did not find any change in BMI, AC, and BP (both SBP and DBP). EE activates the Rennin-AngiotensinAldosterone system, leading to fluid and electrolyte retention. This in turn can raise the body weight and BP. DRSP on the other hand, because of its unique antimineralocorticoid activity, induces sodium excretion and a compensatory rise in rennin secretion, plasma rennin activity, angiotensin II, and plasma aldosterone (18) . Our study found that EE/DRSP does not alter serum glucose or insulin level even after 12 months of treatment. Consequently, there is no change in fasting glucose: insulin ratio or, in other (20) stated that EE/DRSP might be considered neutral with respect to insulin resistance. Pehlivanov et al. (21) reported that in Europe, the most widely used combined oral pill in women with PCOS is a combination of EE (35 mcg) and 2 mg cyproterone acetate. However, the present study shows that the EE/DRSP can be a reasonable alternative. Lack of a control group is a major limitation of the study. A larger study will help to establish whether this combination has any effect on insulin resistance and compare the same with similar agents. The originality of the study is that it has been carried out among the Indian population. Considering the unique Indian population structure with strictly defined endogamous and genetically homogeneous populations, the result of this present study is an enriching experience for any clinician, particularly in the Indian subcontinent interested in the treatment of the polycystic ovary syndrome. Further, this study shows that the response to treatment is the same as that in Western countries.
